Senator Paul seeks contempt vote over Fauci testimony as Trump administration alters asylum rules and Medicare drug subsidies
Sen. Rand Paul plans a vote to hold Dr. Anthony Fauci in contempt after the scientist invoked the Fifth Amendment, while the Trump administration announced a rule allowing asylum officers to bypass interviews and signaled an early end to Medicare drug subsidies.
Sen. Rand Paul (R-Ky.) announced he will move a vote next week to hold Dr. Anthony Fauci in contempt of Congress after the former White House coronavirus adviser refused to answer questions during a Senate Health Committee hearing, invoking his Fifth Amendment right against self-incrimination. Paul previously released more than 1,000 pages of Fauci’s pandemic diary entries, alleging the scientist concealed information about COVID-19’s origins. > "Invoking the Fifth Amendment doesn’t equate to admitting wrongdoing," NPR legal analyst Ari Daniel said. The Biden administration granted Fauci a blanket pardon covering 2014-2025, but legal experts warn he could still face perjury charges if his testimony conflicts with prior statements.
The Trump administration unveiled a new asylum policy that permits asylum officers to refer certain cases directly to immigration court without first conducting an interview with a U.S. Citizenship and Immigration Services officer. The change comes amid a broader tightening of asylum eligibility, with approval rates at their lowest in two decades, and as hundreds of thousands of individuals facing loss of Temporary Protected Status seek alternative legal pathways. Former asylum officer Matt Joseph, now with the Center for Gender and Refugee Studies, described the policy shift as a "concerted attack on asylum from all fronts."
Separately, the administration signaled it will end the Medicare drug-price subsidies a year earlier than planned, potentially raising premiums for millions of beneficiaries. The subsidies, part of the Inflation Reduction Act of 2022, were intended to cap out-of-pocket costs for seniors at $2,000 beginning in 2025 and to stabilize insurer premiums through 2027. Their early termination could increase costs for Medicare drug plans starting next year.